Oxacyclotetradecane Erythromycin Derivative(CAS: 144604-03-5)

Oxacyclotetradecane Erythromycin Derivative (CAS 144604-03-5) is subject to the Globally Harmonized System of Classification and Labelling of Chemicals (GHS), REACH regulations, and FDA/EPA requirements. It must be labeled with appropriate hazard statements, and safety data sheets must be available. Companies must ensure compliance with these guidelines to ensure safe handling and storage.

There are alternative erythromycin derivatives used in synthesis, such as desosymycin and spiramycin derivatives. These can serve as substitutes due to similar structural and biological properties. Researchers often explore these alternatives to optimize reaction conditions and improve yields.

The market for Oxacyclotetradecane Erythromycin Derivative (CAS 144604-03-5) shows steady growth, driven by increasing demand in the pharmaceutical and biotechnology sectors. Research trends focus on its potential applications in treating bacterial infections and its use as a precursor in the synthesis of antibiotics. Emerging studies are also exploring its efficacy and safety in clinical trials.

Waste containing Oxacyclotetradecane Erythromycin Derivative (CAS 144604-03-5) should be collected in appropriate containers and stored in a secure, ventilated area. It should then be disposed of through professional waste disposal services that comply with local environmental regulations. Proper documentation and labeling are essential to ensure safe and compliant disposal.